Active Filter(s):
Details:
Under the terms of the agreement, Harrow Health will have marketing rights for the U.S. and Canada, while Wakamoto Pharmaceuticals will retain MAQ-100 marketing rights in other countries. Wakamoto will supply Harrow with MAQ-100.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: MaQaid
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Harrow Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 18, 2021